Protocol
10-117
Full Title
Single-Arm, Dose-Finding Pilot Trial of Single-agent Bortezomib in Patients with Relapsed/refractory AIDS-Associated Kaposi Sarcoma with Correlative Assessments of KSHV and HIV (AMC 063)
Purpose
Kaposi’s sarcoma (KS) is a type of cancer that is very common in people with AIDS. Treatments for KS do not cure the disease, and better treatments are needed.
The purpose of this study is to evaluate the effectiveness of bortezomib in patients with AIDS-related KS. Bortezomib is used to treat cancers called multiple myeloma and mantle cell lymphoma. Its use in people with KS is considered investigational.
Bortezomib may help stop HIV from progressing and stop the growth of cancer cells. It may also cause the KS herpes virus that lives in KS tumor cells to enter an active state that kills the tumor cells.
Investigator
Co-Investigators
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have Kaposi’s sarcoma and HIV infection.
- Patients must have sufficient KS tissue for biopsy.
- Patients must have disease that has persisted or returned despite prior treatment that included liposomal anthracycline.
- At least 4 weeks must have passed since completion of prior treatment for KS and entry into the study.
- Patients must be have been taking antiretroviral treatment for HIV for at least 12 weeks prior to study entry, and continue to take it during the study.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Mark A. Dickson at 646-888-4166.
Disease(s)
AIDS-Associated Cancers
AIDS-Associated Cancers: AIDS-Associated Kaposi's Sarcoma
Locations
Related Diseases
